Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Tarsus (NASDAQ:TARS) announced it will host a live webcast on Thursday, August 6, 2026, at 5:00 a.m. PT / 8:00 a.m. ET to report its second quarter 2026 financial results and provide a corporate update.
Rhea-AI Summary
Tarsus (NASDAQ:TARS) announced it will host a live webcast on Thursday, August 6, 2026, at 5:00 a.m. PT / 8:00 a.m. ET to report its second quarter 2026 financial results and provide a corporate update. A recorded version will be available on the company’s website for about 90 days after the webcast.
Positive
- None.
Negative
- None.
Details
News Market Reaction – TARS
In the Aug 6 session, TARS gained 6.59%, reflecting a notable positive market reaction. Argus tracked a peak move of +13.0% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Webcast time
- 5:00 a.m. PT / 8:00 a.m. ET
- August 6, 2026
- Reporting date
- August 6, 2026
- Second quarter 2026 financial results
- Replay archive
- Approximately 90 days
- Recorded webcast availability
Previous Earnings date Reports
-
Scheduled first-quarter results webcast and corporate update for May 6, 2026.
-
Scheduled fourth-quarter and full-year results webcast and corporate update for February 23, 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Thursday, August 6, 2026 to report its second quarter 2026 financial results and provide a corporate update.
Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution)
Media Contact:
Adrienne Kemp
Vice President, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.